This study aimed to determine the incidence of meniscal tears and describe the tear morphology and selected treatment in patients undergoing anterior cruciate ligament (ACL) reconstruction. We also will discuss the potential market for future tissue engineering aimed at preserving meniscal function. A multicenter cohort of 1014 patients undergoing ACL reconstruction between January 2002 and December 2003 was evaluated. Data on patient demographics, presence of a meniscus tear at time of ACL reconstruction, tear morphology, and meniscal treatment were collected prospectively. Meniscal tears were categorized into 3 potential tissue engineering treatment strategies: all-biologic repair, advanced repair, and scaffold replacement. Of the knees, 36% had medial meniscal tears and 44% had lateral meniscal tears. Longitudinal tears were the most common tear morphology. The most frequent treatment method was partial meniscectomy. Thirty percent of medial meniscal tears and 10% of lateral meniscal tears are eligible for all-biologic repair; 35% of medial meniscal tears and 35% of lateral meniscal tears are eligible for an advanced repair technique; and 35% of medial meniscal tears and 55% of lateral meniscal tears are eligible for scaffold replacement. Although meniscal preservation is generally accepted in the treatment of meniscal tears, most tears in this cohort were not repairable, despite contemporary methods. The results of this cohort will hopefully stimulate and focus future research and development of new tissue engineering strategies for meniscus repair.
"Knowing the risk for the onset of osteoarthritis after meniscectomy, the majority of meniscus tears are still treated with partial meniscectomy as shown in a huge cohort of more than 1000 young patients undergoing anterior cruciate ligament reconstruction (Fetzer et al. 2009). Therefore, the main goal of every meniscus treatment should be the maintenance of as much meniscus tissue as possible (Fetzer et al. 2009; Starke et al. 2009; Stein et al. 2010; Abrams et al. 2013). This includes repair of meniscus tears and regeneration of meniscus defects after meniscectomy with regenerative treatment approaches. "
[Show abstract][Hide abstract] ABSTRACT: The central control computer of the ARCS (Autonomous Remotely Controlled Submersible) consists of three microprocessors residing on a common bus and communicating with each other via shared memory. This paper will review the general design approach used to meet the operational requirements of the vehicle, and discuss the types of problems encountered during implementation and preliminary testing.
Unmanned Untethered Submersible Technology, Proceedings of the 1985 4th International Symposium on; 07/1985
[Show abstract][Hide abstract] ABSTRACT: This article proposes a "bedside-to-bench" approach as a model to improve clinical outcomes for patients through functional tissue engineering (TE). The link between the highest level of clinical research and evaluation criteria for musculoskeletal TE is in identifying clinically proven predictors that are amenable to functional TE. The TE solutions developed in the laboratory should then be tested in translational models to evaluate efficacy and safety prior to controlled clinical trials. The best available evidence for potentially decreasing the incidence of radiographically confirmed osteoarthritis after anterior cruciate ligament injury is preservation of meniscus function. Meniscus tears occur concurrently in approximately 50% of anterior cruciate ligament tears. TE could promote repair of torn meniscus and/or replacement of meniscus loss because meniscus tear is a proven predictor of clinically relevant outcomes (such as osteoarthritis) in patients and is amenable to a potential TE solution.
Tissue Engineering Part B Reviews 02/2010; 16(1):117-21. DOI:10.1089/ten.teb.2009.0302 · 4.64 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.